WO2006126523A1 - 腹膜保護剤 - Google Patents
腹膜保護剤 Download PDFInfo
- Publication number
- WO2006126523A1 WO2006126523A1 PCT/JP2006/310220 JP2006310220W WO2006126523A1 WO 2006126523 A1 WO2006126523 A1 WO 2006126523A1 JP 2006310220 W JP2006310220 W JP 2006310220W WO 2006126523 A1 WO2006126523 A1 WO 2006126523A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peritoneal
- group
- pyridoxamine
- peritoneum
- pyridoxine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
- A61M1/28—Peritoneal dialysis ; Other peritoneal treatment, e.g. oxygenation
- A61M1/287—Dialysates therefor
Definitions
- the present invention relates to a peritoneal protective agent containing pyridoxine such as pyridoxamine as an active ingredient.
- Non-patent Documents 1 and 5 The molecular mechanism underlying peritoneal dysfunction has not yet been elucidated. Recurrence of peritonitis accompanied by inflammatory changes damages the peritoneum for a long time [Non-patent Documents 1 and 5], but is not a condition for the onset of ultrafiltration failure [Non-patent Documents 4 and 6]. Recent studies have inferred and elucidated the mechanism of peritoneal decline in long-term PD patients [7–14]. Chronic uremia itself changes the peritoneum and increases EPSA [Non-Patent Document 8].
- Peritoneal biochemical changes are due, at least in part, to the overload of highly reactive carbo-Rich compounds (RCO) by both uremic circulation and PD fluid (“peritoneal carbonyl stress”). ) Seems to be the cause [Non-Patent Documents 9-14].
- Plasma RCO accumulates in the uremic circulation, gradually diffuses into the peritoneal cavity, and initiates modification of the late glycation end product (AGE) [Non-patent Documents 15 to 21].
- AGE late glycation end product
- RCO resulting from heat sterilization of glucose PD solution enters the peritoneum. These are supplemented by an increase in mass transfer of serum RCO by the dialysis treatment itself.
- This peritoneal carbonyl stress force structurally promotes irreversible AGE modification of peritoneal proteins.
- This RCO further stimulates the production of cytoforce-ins and growth factors (such as VEGF), and nitric oxide synthase (NO) in peritoneal cells. It appears to regulate the expression of S) [Non-Patent Documents 22 to 25].
- VEGF and nitric oxide (NO) work together to stimulate angiogenesis and increase permeability! To expand the peritoneal capillaries [Non-patent Documents 23 to 25]. These combined changes will increase EPSA, which will cause the osmotic pressure to disappear earlier than normal and ultimately prevent ultrafiltration. Up-regulation of FGF-2 and TGF-
- Non-patent literature l Davies SJ, et al., Kidney Int 54: 2207-2217, 1998
- Non-Patent Document 2 Krediet RT, etc., Perit Dial Bull 6: 61-65, 1986
- Non-Patent Document 4 Krediet RT, etc., Kidney Int 55: 341-356, 1999
- Non-Patent Document 5 Krediet RT, etc., Ave Ren Replace Ther 5: 212-217, 1994
- Non-Patent Document 6 Struijk SG, et al., Kidney Int 45: 1739-1744, 1994
- Non-Patent Document 7 Davies SJ, et al., Nephrol Dial Transplant 11: 448-506, 1996
- Non-Patent Document 8 Combet S, et al., J Am Soc Nephrol 12: 2146-2157, 2001
- Non-Patent Document 9 Korbet SM, etc., Am J Kidney Dis 22: 588-591, 1993
- Non-Patent Document 10 Miyata T, et al., Kidney Int 2002; 61: 375-386
- Non-patent literature ll Nakayama M, et al., Kidney Int 51: 182-186, 1997
- Non-Patent Document 12 Miyata T, et al., Kidney Int 58: 425-435, 2000
- Non-Patent Document 13 Witowski J, et al., J Am Soc Nephrol 11: 729-739, 2000
- Non-Patent Document 14 Wieslander A, etc., Adv Perit Dial 12: 57-60, 1996
- Non-Patent Document 15 Garcia-Lopez E, et al., Perit Dial Int 20 (Suppl 5): S48-S56, 2000
- Non-patent Document 16 Krediet RT, et al., Perit Dial Int 17: 35-41, 1997
- Non-Patent Document 17 Faller B, et al., Kidney Int (Supple 56): S81-S85, 1996
- Non-Patent Document 18 Rippe B, et al., Kidney Int 59: 348-357, 2001
- Non-Patent Document 19 Topley N, Perit Dial Int 17: 42-47, 1997
- Non-Patent Document 20 Feriani M, et al., Kidney Int 54: 1731-1738, 1998
- Non-patent document 21 Rhein C, et al., Perit Dial Int 20 (Suppl 5): S28-S32, 2000
- Non-patent document 22 Papapetropoulos A, et al., J Clin Invest 100: 3131-3139, 1997
- Non-patent document 23 Vriese AS, et al., J Am Soc Nephrol 12: 2029-2039, 2001
- Non-Patent Document 24 Margetts PJ, et al., J Am Soc Nephrol 12: 2029-39, 2001
- Non-Patent Document 25 Combet S, et al., J Am Soc Nephrol 11: 717-728, 2000
- Non-Patent Document 26 Ogata S, et al., J Am Soc Nephrol 12: 2787-2796, 2001
- An object of the present invention is to provide a novel peritoneal protective agent capable of effectively suppressing a decrease in peritoneal function in a long-term peritoneal dialysis (PD) patient or the like.
- peritoneal dysfunction and ultrafiltration failure in patients with long-term peritoneal dialysis are reactive carboxylic compounds (both by uremic circulation and heat sterilization of glucose PD solution).
- RCO peritoneal carbo-stress
- a subtotal nephrectomy uremic rat model This was followed by PD using a common glucose-based dialysate, and pyridoxamine (the recently developed late glycation end product (AGE) and carbonyl stress on peritoneal structural, functional and biochemical changes.
- pyridoxamine the recently developed late glycation end product (AGE) and carbonyl stress on peritoneal structural, functional and biochemical changes.
- the protective effect of (a potent inhibitor) was evaluated. As a result, it was confirmed that pyridoxamine exhibited a peritoneal protective action, and the present invention was completed.
- a peritoneal protective agent comprising pyridoxine or a salt thereof as an active ingredient is provided.
- the pyridoxine is pyridoxamine.
- the peritoneal protective agent of the present invention is used to treat and Z or prevent peritoneal dysfunction or ultrafiltration failure in peritoneal dialysis patients.
- a method for protecting the peritoneum comprising the step of administering an effective amount of pyridoxine or a salt thereof to a mammal including a human.
- pyridoxines for the manufacture of a peritoneal protective agent or Use of the salt is provided.
- a uremia rat model of subtotal nephrectomy is used, and PD is performed using a common glucose-based dialysis solution, and pyridoxamine for structural, functional and biochemical changes of the peritoneum is performed.
- AGEs recently developed late glycation end products
- potent inhibitors of carbonyl stress were evaluated.
- the peritoneum increases the functional exchange area of small molecule solutes between blood and dialysate, increases vascular proliferation, increases AGF production, and induces cytodynamic force (ie VEGF And characterized by upregulation of FGF-2) expression.
- the functional, structural, and biochemical changes of the peritoneum associated with PD are similar, but more severe than in patients with chronic uremia who have not received PD.
- Pyridoxamine administered to uremic rats undergoing PD significantly reduced the transport rate and vascular density of small molecule solutes, a result indicating the beneficial role of pyridoxamine for ultrafiltration failure. This improvement was accompanied by a decrease in the expression of site force-inducing AGE accumulation and angiogenesis.
- the uremia environment and peritoneal carbo-stress caused by PD treatment contribute to the increase in the functional exchange area of vascular proliferation and small molecule solutes induced by bioactive molecules, and ultimately Leads to ultrafiltration failure.
- treatment with pyridoxamine significantly reduced the transport rate of small molecule solutes from plasma and the rate of glucose absorption as much as dialysate.
- treatment with pyridoxamine almost completely abolished the effect of uremia on membrane permeability.
- This improvement in peritoneal function was accompanied by an increase in angiogenesis induced by uremia and PD, and a suppression of the expression of site force-in that induces angiogenesis.
- intervention with pyridoxamine significantly reduced the tissue pentosidine content.
- pyridoxamine can protect the peritoneum of uremic patients undergoing PD by improving the functional, structural and molecular biochemical changes of the peritoneum.
- the present invention relates to a peritoneal protective agent containing pyridoxine or a salt thereof as an active ingredient.
- pyridoxines used as active ingredients in the present invention include pyridoxine, pyridoxal, pyridoxamine, and salts thereof.
- the aforementioned pyridoxine, pyridoxal and pyridoxamine are compounds represented by the following formulae.
- R is CH OH (for pyridoxine), CHO (for pyridoxal) or C
- H represents NH (in the case of pyridoxamine).
- Pyridoxine salts include inorganic acid salts such as pyridoxine hydrochlorides, sulfates, nitrates, and phosphates, or organic acid salts such as maleates, fumarate, kenates, and acetates. can give.
- pyridoxine phosphate, pyridoxal phosphate, or pyridoxamine phosphate is particularly preferable.
- Pyridoxine or a salt thereof may exist in the form of a hydrate or a solvate. Pyridoxine or a salt thereof can be synthesized by a known method, or can be purchased as a commercial product.
- the peritoneal protective agent of the present invention can be provided in the form of a pharmaceutical composition containing pyridoxine as an active ingredient and optionally containing additives for formulation.
- the pharmaceutical composition can be prepared by blending the active ingredient pyridoxine in combination with a pharmaceutically acceptable carrier.
- Examples of the pharmaceutically acceptable carrier include physiological saline, Ringer's solution, phosphate buffered physiological saline, and other carriers known to those skilled in the art, but are not limited thereto.
- Pharmaceutical compositions include, for example, stabilizers, antioxidants, colorants, excipients, binders, thickeners, dispersants, resorption enhancers, buffers, surfactants, preservatives, emulsifiers, etc.
- One or more additives such as tonicity agents and diluents may be included.
- the above pharmaceutically acceptable carriers and additives are pyridoxines which are active ingredients It is desirable to select such that the side effects of pyridoxines are minimized and the inhibition of the efficacy of pyridoxines is reduced.
- a method for preparing a pharmaceutical composition containing a combination of pyridoxine and a pharmaceutically acceptable carrier and Z or a carotenant is known to those skilled in the art.
- the pharmaceutical composition when the peritoneal protective agent of the present invention is orally administered as a suspension, the pharmaceutical composition includes microcrystalline cellulose, alginic acid or sodium alginate as a suspension, methylcellulose as a thickener. , And fragrances can be blended.
- the pharmaceutical composition when preparing immediate release tablets, the pharmaceutical composition includes microcrystalline cellulose, starch, magnesium stearate and lactose or other excipients, binders, extenders, disintegrants, diluents and A lubricant or the like can be blended.
- a suitable oil such as an oil containing a sterilized synthetic mono- or diglyceride and a fatty acid containing oleic acid is used.
- injectable solutions or suspensions may be prepared using dispersing or wetting agents and suspending agents.
- peritoneal protective agent of the present invention When the peritoneal protective agent of the present invention is administered rectally as a suppository, an appropriate dosage such as cocoa butter, a synthetic glyceride ester or polyethylene glycol which is solid at room temperature but dissolves in the rectal cavity to release the drug is used. Suppositories can be prepared by mixing the form with pyridoxines.
- the administration route of the peritoneal protective agent of the present invention is not particularly limited, and is orally or parenterally administered.
- subcutaneous administration intramuscular administration, intradermal administration, intravenous administration, etc.
- intramuscular administration intramuscular administration, intradermal administration, intravenous administration, etc.
- the peritoneal protective agent of the present invention is a solid preparation
- the content of pyridoxine contained in the solid preparation is usually 0.01 to 30% by weight, preferably 0.1 to 20% by weight.
- the peritoneal protective agent of the present invention is a liquid
- the content of pyridoxine contained in the liquid is usually 0.1 to 20 mg / mL, preferably 1 to LOmg / mL.
- the dose and frequency of administration of the peritoneal protective agent of the present invention should be appropriately set depending on various factors including the purpose of administration, dosage form, dosage form, age, weight, sex, etc. of the recipient. Can do. In general, the dose is in the range of about 0.1 to LOOmgZkg, preferably about 0.5 to 50 mgZkg, per dose as the dose of the active ingredient pyridoxine. It is preferable to administer the above-mentioned dosage in about 1 to 4 times a day. Of the present invention
- the administration period of the peritoneal protective agent is not limited sometimes, and may be administered for a short period (for example, 1 day to several weeks) or for a long period (for several weeks to one month or more).
- the peritoneal protective agent of the present invention can be used to treat and Z or prevent peritoneal dysfunction or ultrafiltration failure in peritoneal dialysis patients.
- treatment includes healing, improving peritoneal dysfunction or ultrafiltration insufficiency, or suppressing progression to alleviate bad habits.
- prevention in this specification includes preventing the occurrence of peritoneal dysfunction or ultrafiltration failure, or preventing the deterioration of the condition.
- the peritoneum is treated by administering to a patient (for example, a peritoneal dialysis patient) an effective amount of pyridoxine for the treatment or prevention of peritoneal dysfunction or ultrafiltration failure.
- a patient for example, a peritoneal dialysis patient
- an effective amount of pyridoxine for the treatment or prevention of peritoneal dysfunction or ultrafiltration failure.
- Rat-o-ports were implanted subcutaneously in the cervix, and after 1 week, peritoneal dialysis was started twice a day with 30 ml of dialysate and continued for 6 weeks thereafter [Zweers MM, et al., Nephrol Dial Transplant 16 : 651-654, 2001]. Before the start of peritoneal permeation, 4, 5 and 2 rats died in Group 2, Group 3 and Group 4, respectively.
- Dianil registered trademark
- a peritoneal equilibrium test 60 minutes was performed. Thereafter, the rats were euthanized by anesthesia. Heparin blood plasma collected in the 2nd week was separated. The mesentery was removed and evaluated by light microscopy or immunohistochemistry.
- the concentrations of glucose, creatine, urea, total cholesterol and triglyceride in plasma and peritoneal dialysate were measured with an automatic analyzer (HitacW model 736-60, Hitachi Electronics Co., Ltd.).
- pentosidine in the rat peritoneum was evaluated using HPLC according to a previously reported method [Miyata T, et al., J. Am. So Nephrol 7: 1198-1206, 1996].
- Peritoneal tissue 100 mg was homogenized with 1.5 ml of chloroform / methanol (2: 1) followed by 1.0 ml of methanol to remove the lipids, dried under vacuum, 500 ⁇ l of 6 ⁇ HC1 Hydrolyzed at 110 ° C for 16 hours.
- the acid hydrolyzate was dried in vacuo, reconstituted with 400 1 10 mM HC1, filtered through a 0.5 ⁇ m pore size filter and diluted with PBS.
- the diluted sample was injected into the HPLC apparatus and separated on a C18 reverse phase column (5 / ⁇ ⁇ , 4.6 X 250 mm: Waters, Tokyo).
- the eluate was monitored using a fluorescence detector (RF-10A: Shimadzu Corporation, Tokyo) and an excitation / emission wavelength of 335/385 nm.
- Synthetic pentosidine [Miyata T, et al., J. Am. So Nephrol 7: 1198-1206, 1996 ] was used to create a standard curve.
- Immunohistochemical analysis was performed using formalin-fixed and paraffin-embedded sections. 4 ⁇ slices were prepared from paraffin blocks, deparaffinized and dehydrated by immersion in graded concentrations of ethanol. As primary antibodies, anti-TGF-jS 1 antibody (1:40, Santa Cruz Biotechnology, Santa Cruz, CA), anti-von'Villebrand factor antibody (1: 400, Daco, Denmark, Gullstrap), anti-VEGF antibody ( 1: 100, Santa Cruz Biotechnology) ⁇ Anti-FGF-2 antibody (1: 400, Santa Cruz Biotechnology) and anti-AGE antibody (1: 200, Transgenic, Kumamoto) were used. The sections were deparaffinized with xylene and dehydrated with ethanol. The sections are soaked in methanol containing 0.3% H0 for 10 minutes at room temperature.
- Inhibited oxidase activity Antigenic activation by heating was performed. After washing with phosphate buffered saline (pH 7.4), the sections (anti-TGF-jS 1, von Willebrand factor, FGF2, VEG F antibody) were electronized in 0.01M citrate buffer (pH 6.0). Heated in the range (500W) at 100 ° C for 10 minutes. The primary antibody was collected and incubated at room temperature for 1 hour. Thereafter, the sections were rinsed, incubated with a secondary antibody (Nichirei, Tokyo) for 45 minutes, immersed in 0.2% 3,3-diaminobenzidine tetrahydrochloride (DAB), and then counterstained with hematoxylin. The specificity of the immunolabeling was examined using non-immune rabbit or goat IgG.
- DAB 3,3-diaminobenzidine tetrahydrochloride
- the number of blood vessels was evaluated by image analysis using WinROOF software (Mitani Corporation, Tokyo) on sections stained for von Willebrand factor.
- the average number of capillaries was estimated using a 40x objective lens in 20 fields randomly selected for each cortical region. Results were expressed as the number of healthy control animals.
- RNA expression of VEGF or FGF2 was quantified by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR).
- RT-PCR semi-quantitative reverse transcription polymerase chain reaction
- Total length of amplified fragment is 310bp
- the total length of the amplified fragment is 276 bp
- 8-actin was used as an internal standard to allow comparison of RNA levels in different samples.
- Samples were DNA thermal cycler (Perkin Elmer Cetus, Norwalk, Conn.), 94 ° C for 1 minute for VEGF or FGF2, 58 ° C for 1 minute, 60 ° C for 1 minute for j8-actin, 72 ° C for 1 minute Amplified with the appropriate cycle.
- reverse transcription and PCR amplification were performed for 18, 21, 25, 28, 31, 34, 36 cycles with varying amounts of RNA.
- Table 1 shows the biochemical data and body weight of uremic rats with subtotal nephrectomy.
- uremic rats Groups 2-4
- plasma creatinine, urea, and total cholesterol were significantly increased and body weight decreased compared to non-uremic rats (Group 1).
- Statistical analysis between PD and Z or pyridoxamine treatment in the uremia group showed no significant difference in these values.
- Plasma concentrations of glucose and triglycerides were not statistically different between all groups.
- Peritoneal permeability gradually changes during PD. Using normal glucose-based dialysate V, 6-week PD, small molecule solute transport rate from plasma (Group 2 in Figures 2A and B) and glucose absorption rate of dialysate force (Figure 2C) ) Increased significantly.
- pyridoxamine dramatically reduced the slope of the regression line between increased permeability of small molecule solutes (creature and glucose) and the extent of renal failure. Pyridoxamine treatment almost completely abolished the effect of uremia on membrane permeability.
- Increased EPSA is known to be closely related to increased angiogenesis. Therefore, the number of blood vessels in the peritoneal tissue after von Willebrand factor staining was measured (Fig. 4A). Uremia itself increased the number of blood vessels by 1.87 times, and PD treatment increased its value by 5.83 times. This enhanced angiogenesis was significantly improved up to 2.68 times by pyridoxamine treatment. There was a significant correlation between increased permeability of creatun (Fig. 4B) or glucose (Fig. 4C) and the number of blood vessels. This result implies that increased EPSA during peritoneal function is associated with uremia and PD treatment.
- pentosidine a well-known surrogate marker for AGE and carbo-stress
- HPLC assay of mesenteric tissue Pentosidine content is increased by uremia (group 2 in Fig. 5A), and there is a correlation between the content of pentosidine in the tissue and the degree of renal failure (black circle in Fig. 5B).
- pentosidine was promoted (Group 3 in Figure 5A), and PD increased the slope of the regression line between pentosidine content and renal failure (Figure 4B). Corner).
- the intervention with pyridoxamine significantly reduced the pentosidine content in the tissue (Group 4 in Fig. 5A) and the slope of the regression line (white triangle in Fig. 5B).
- VEGF and FGF-2 were analyzed by semiquantitative PCR.
- Expression of VEGF (Fig. 7B) and FGF-2 (Fig. 7C) in uremic rats was significantly increased by higher PD treatment than in control rats.
- Pyridoxamine reduced the expression of both VEGF and FGF-2 to levels similar to uremic rats without PD.
- 81 in mesenteric tissue sections Fig. 8
- VEGF, FGF-2, vWF, AGE, and TGF-jS 1 staining could not be detected visually in the endothelium of the mesenteric blood vessels of control rats. Slightly present in the peritoneum, it was prominent in uremic rats treated with PD. On the other hand, only weak staining was detected in the capillaries of the mesentery of rats treated with pyridoxamine.
- Pyridoxine such as pyridoxamine used as an active ingredient in the present invention is a safe substance with few side effects. According to the present invention, it has become possible to provide a safe peritoneal protective agent capable of effectively suppressing the decrease in peritoneal function in a long-term peritoneal dialysis (PD) patient or the like.
- PD peritoneal dialysis
- FIG. 1 shows the protocol for animal experiments. Six-week-old rats were assigned to the uremic sham operation group. Five weeks after subtotal nephrectomy, surgical implantation with an intraperitoneal catheter and subcutaneous access port was performed. PD continued until 21 weeks after birth.
- FIG. 2 shows an analysis of peritoneal function by PET.
- Dialysate / plasma ratio (D / P) of Cr (A) and urea (B) during 60 min exchange with 20 ml glucose dialysate, and glucose absorption from dialysate (D / D0) ( C) control rats (Group 1), uremic rats without PD ( (Group 2), uremic rats that received PD without pyridoxamine (Group 3), and uremic rats that received PD with 5 mg / L pyridoxamine (Group 4).
- a p 0.01 for the first group.
- b p ⁇ 0.01 for the second group.
- f p ⁇ 0.05 for group 4.
- FIG. 3 shows a correlation between an increase in the permeability of Creathun (A) or glucose (B) and the degree of renal failure.
- FIG. 4 shows the peritoneal structure analysis by immunohistochemical analysis of von Willebrand factor.
- A Rat mesenteric blood vessel count.
- a p ⁇ 0.01 for the first group.
- b p ⁇ 0.01 for the second group.
- P ⁇ 0.01 for the third group.
- FIG. 5 shows peritoneal AGE content by HPLC assay.
- A Pentosidine content in rat mesentery. a: p ⁇ 0.01 for the first group. b: p ⁇ 0.05 for the fourth group. P 0.05 for the third group.
- B There is a significant correlation between the mesenteric pentosidine content and the degree of creatine permeability due to renal failure.
- Fig. 7 shows detection of expression of cytoforce-in that induces angiogenesis.
- VEGF or FGF2 mRNA expression in the mesentery was analyzed by semi-quantitative reverse transcription polymerase chain reaction (RT-PCR) (A).
- A reverse transcription polymerase chain reaction
- B FGF2
- C FGF2
- a p ⁇ 0.05 for the first group. 1>: ⁇ 0.05 for the second group.
- d p 0.05 for the fourth group.
- e p 0.01 for the first group.
- f p ⁇ 0.01 for the second group.
- g p ⁇ 0.01 for the third group. ⁇ 0.01 for the fourth group.
- FIG. 8 shows immunohistochemical detection of VEGF, FGF2, vWF, AGE, and TGF j81 in the mesentery.
- VEGF vascular endothelial growth factor
- FGF2 FGF2
- vWF vWF
- AGE D
- TGF- ⁇ 1 D
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- External Artificial Organs (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007517830A JPWO2006126523A1 (ja) | 2005-05-24 | 2006-05-23 | 腹膜保護剤 |
EP06756476A EP1908470A4 (en) | 2005-05-24 | 2006-05-23 | MEDIUM FOR THE PROTECTION OF PERITONEUMS |
CA002624090A CA2624090A1 (en) | 2005-05-24 | 2006-05-23 | Peritoneum protecting agent |
AU2006250547A AU2006250547A1 (en) | 2005-05-24 | 2006-05-23 | Peritoneal membrane protecting agent |
US11/915,347 US20090030047A1 (en) | 2005-05-24 | 2006-05-23 | Peritoneum protecting agent |
US12/875,538 US20110021579A1 (en) | 2005-05-24 | 2010-09-03 | Peritoneum protecting agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005-150887 | 2005-05-24 | ||
JP2005150887 | 2005-05-24 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/875,538 Division US20110021579A1 (en) | 2005-05-24 | 2010-09-03 | Peritoneum protecting agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006126523A1 true WO2006126523A1 (ja) | 2006-11-30 |
Family
ID=37451948
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/310220 WO2006126523A1 (ja) | 2005-05-24 | 2006-05-23 | 腹膜保護剤 |
Country Status (8)
Country | Link |
---|---|
US (2) | US20090030047A1 (ja) |
EP (1) | EP1908470A4 (ja) |
JP (1) | JPWO2006126523A1 (ja) |
KR (1) | KR20080034845A (ja) |
CN (1) | CN101227904A (ja) |
AU (1) | AU2006250547A1 (ja) |
CA (1) | CA2624090A1 (ja) |
WO (1) | WO2006126523A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012011588A1 (ja) * | 2010-07-23 | 2012-01-26 | 学校法人東海大学 | 腹膜透析患者用の経口医薬組成物及びその用法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014186052A2 (en) * | 2013-05-17 | 2014-11-20 | Thomson Licensing | Method and system for providing location scouting information |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH10324629A (ja) * | 1997-03-28 | 1998-12-08 | Otsuka Pharmaceut Co Ltd | Age生成阻害組成物 |
JPH11512432A (ja) * | 1995-09-12 | 1999-10-26 | ユニヴァースティ オブ カンザス メディカル センター | 前進性グリケーション最終産物の中間体とアマドリ転位後の阻害 |
WO2000010606A1 (fr) * | 1998-08-24 | 2000-03-02 | Kurokawa, Kiyoshi | Medicaments de sedation de l'agression du carbonyle et des dialysats peritoneaux |
JP2001513370A (ja) * | 1997-08-07 | 2001-09-04 | グプタ,アジャイ | 水溶性ビタミン及び栄養素を含む透析溶液 |
JP2001523663A (ja) * | 1997-11-17 | 2001-11-27 | ユニヴァースティ オブ カンザス メディカル センター | 進歩した糖化最終生成物中間体及び後−アマドリ阻害 |
JP2002527471A (ja) * | 1998-10-22 | 2002-08-27 | ユニヴァースティ オブ サウス カロライナ | 糖尿病合併症を阻害する方法 |
JP2004300153A (ja) * | 2003-03-20 | 2004-10-28 | Kiyoshi Kurokawa | 蛋白修飾物生成抑制剤 |
WO2005018649A1 (ja) * | 2003-08-25 | 2005-03-03 | Nagoya Industrial Science Research Institute | 最終糖化産物生成抑制剤 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5717976A (en) * | 1995-08-28 | 1998-02-10 | Eastman Kodak Company | Stack of sheets and method of assuring orientation |
US6740668B1 (en) * | 1995-08-28 | 2004-05-25 | Kansas University Medical Center | Methods for inhibiting diabetic complications |
US6436969B1 (en) * | 1995-09-12 | 2002-08-20 | Kansas University Medical Center Research Institute Inc. | Dialysis solutions and methods |
WO2005077902A2 (en) * | 2004-02-09 | 2005-08-25 | Biostratum, Inc. | Methods for the synthesis of pyridoxamine |
-
2006
- 2006-05-23 US US11/915,347 patent/US20090030047A1/en not_active Abandoned
- 2006-05-23 KR KR1020077030099A patent/KR20080034845A/ko not_active Application Discontinuation
- 2006-05-23 WO PCT/JP2006/310220 patent/WO2006126523A1/ja active Application Filing
- 2006-05-23 CN CNA2006800270502A patent/CN101227904A/zh active Pending
- 2006-05-23 JP JP2007517830A patent/JPWO2006126523A1/ja active Pending
- 2006-05-23 EP EP06756476A patent/EP1908470A4/en not_active Withdrawn
- 2006-05-23 CA CA002624090A patent/CA2624090A1/en not_active Abandoned
- 2006-05-23 AU AU2006250547A patent/AU2006250547A1/en not_active Abandoned
-
2010
- 2010-09-03 US US12/875,538 patent/US20110021579A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11512432A (ja) * | 1995-09-12 | 1999-10-26 | ユニヴァースティ オブ カンザス メディカル センター | 前進性グリケーション最終産物の中間体とアマドリ転位後の阻害 |
JPH10324629A (ja) * | 1997-03-28 | 1998-12-08 | Otsuka Pharmaceut Co Ltd | Age生成阻害組成物 |
JP2001513370A (ja) * | 1997-08-07 | 2001-09-04 | グプタ,アジャイ | 水溶性ビタミン及び栄養素を含む透析溶液 |
JP2001523663A (ja) * | 1997-11-17 | 2001-11-27 | ユニヴァースティ オブ カンザス メディカル センター | 進歩した糖化最終生成物中間体及び後−アマドリ阻害 |
WO2000010606A1 (fr) * | 1998-08-24 | 2000-03-02 | Kurokawa, Kiyoshi | Medicaments de sedation de l'agression du carbonyle et des dialysats peritoneaux |
JP2002527471A (ja) * | 1998-10-22 | 2002-08-27 | ユニヴァースティ オブ サウス カロライナ | 糖尿病合併症を阻害する方法 |
JP2004300153A (ja) * | 2003-03-20 | 2004-10-28 | Kiyoshi Kurokawa | 蛋白修飾物生成抑制剤 |
WO2005018649A1 (ja) * | 2003-08-25 | 2005-03-03 | Nagoya Industrial Science Research Institute | 最終糖化産物生成抑制剤 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012011588A1 (ja) * | 2010-07-23 | 2012-01-26 | 学校法人東海大学 | 腹膜透析患者用の経口医薬組成物及びその用法 |
JP5128003B2 (ja) * | 2010-07-23 | 2013-01-23 | 学校法人東海大学 | 腹膜透析患者用の経口医薬組成物及びその用法 |
EP2596789A4 (en) * | 2010-07-23 | 2014-01-01 | Univ Tokai Educational System | ORALLY DELIVERABLE PHARMACEUTICAL COMPOSITION FOR PATIENT UNDER PERITONEAL DIALYSIS, AND IMPLEMENTATION THEREOF |
Also Published As
Publication number | Publication date |
---|---|
KR20080034845A (ko) | 2008-04-22 |
EP1908470A1 (en) | 2008-04-09 |
US20110021579A1 (en) | 2011-01-27 |
CN101227904A (zh) | 2008-07-23 |
JPWO2006126523A1 (ja) | 2008-12-25 |
AU2006250547A1 (en) | 2006-11-30 |
US20090030047A1 (en) | 2009-01-29 |
EP1908470A4 (en) | 2009-06-24 |
CA2624090A1 (en) | 2006-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Breborowicz et al. | Toxicity of osmotic solutes on human mesothelial cells in vitro | |
JP5815581B2 (ja) | イコデキストリンを含有する生体適合性透析液 | |
Schulman et al. | Complement activation retards resolution of acute ischemic renal failure in the rat | |
Manns et al. | Continuous renal replacement therapies: an update | |
Tolins et al. | Comparison of converting enzyme inhibitor and calcium channel blocker in hypertensive glomerular injury. | |
US7875183B2 (en) | Method of removing antibody free light chains from blood | |
Canaud et al. | On‐line haemodiafiltration. Safety and efficacy in long‐term clinical practice | |
Kopple | 1995 Jonathan E. Rhoads Lecture. The Nutrition Management of the Patient With Acute Renal Failure | |
Kakuta et al. | Pyridoxamine improves functional, structural, and biochemical alterations of peritoneal membranes in uremic peritoneal dialysis rats | |
Nolph | What's new in peritoneal dialysis--An overview. | |
Hughes et al. | Acute liver failure. | |
Carson et al. | Removal of plasma porphyrins with high-flux hemodialysis in porphyria cutanea tarda associated with end-stage renal disease. | |
WO2006126523A1 (ja) | 腹膜保護剤 | |
Canaud | Online hemodiafiltration | |
Canaud et al. | Online hemodiafiltration: a multipurpose therapy for improving quality of renal replacement therapy | |
Rubin et al. | The importance of the abdominal viscera to peritoneal transport during peritoneal dialysis in the dog | |
Rippe | Peritoneal angiogenesis in response to dialysis fluid | |
Park | Factors increasing severity of peritonitis in long-term peritoneal dialysis patients | |
Nolph | Update on peritoneal dialysis worldwide | |
Gokal et al. | Historical developments and overview of peritoneal dialysis | |
Canaud et al. | Ultrafiltration and convective-based dialysis modalities: new trends and applications for renal replacement therapy in ESRD patients | |
Gotloib | Hemofiltration in multiorgan failure syndrome secondary to sepsis: A critical analysis of heterogeneity | |
Grootendorst et al. | Blood purification by hemofiltration in septic shock and multiple organ dysfunction syndrome patients | |
Schrander-vd Meer et al. | Dialysis efficacy during acetate-free biofiltration. | |
Hobby et al. | Fucidin in patients on haemodialysis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680027050.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007517830 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006756476 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006250547 Country of ref document: AU Ref document number: 1020077030099 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: 2006250547 Country of ref document: AU Date of ref document: 20060523 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2006250547 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2624090 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 11915347 Country of ref document: US |